<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028730</url>
  </required_header>
  <id_info>
    <org_study_id>01-105</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>P01CA033049</secondary_id>
    <secondary_id>P01CA023766</secondary_id>
    <secondary_id>MSKCC-01105</secondary_id>
    <secondary_id>NCI-H01-0083</secondary_id>
    <nct_id>NCT00028730</nct_id>
  </id_info>
  <brief_title>Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer</brief_title>
  <official_title>Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow&#xD;
      transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's&#xD;
      immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor&#xD;
      are infused into the patient they may help the patient's bone marrow make stem cells, red&#xD;
      blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor&#xD;
      can make an immune response against the body's normal cells. Giving antithymocyte globulin&#xD;
      and removing the T cells from the donor cells before transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well total-body irradiation and chemotherapy&#xD;
      followed by T-cell depleted donor bone marrow transplant works in treating young patients&#xD;
      with hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of hyperfractionated total body irradiation, thiotepa, and&#xD;
           cyclophosphamide followed by T-cell-depleted allogeneic bone marrow transplantation in&#xD;
           children with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous&#xD;
           leukemia, non-Hodgkin's lymphoma, or myelodysplastic syndromes.&#xD;
&#xD;
        -  Correlate the progenitor cell dose and dose of clonable T cells with the incidence and&#xD;
           quality of engraftment, extent of chimerism, incidence and severity of acute and chronic&#xD;
           graft-versus-host disease, characteristics of hematopoietic and immunologic&#xD;
           reconstitution, and overall and disease-free survival at 2 years in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: Patients undergo total body irradiation three times daily on days -9 to -7 and twice&#xD;
      on day -6. Patients receive thiotepa IV over 4 hours on days -5 and -4 and cyclophosphamide&#xD;
      IV over 30 minutes on days -3 and -2. Patients who cannot receive cyclophosphamide, due to&#xD;
      prior hemorrhagic cystitis or exposure to high-dose cyclophosphamide or ifosfamide, receive&#xD;
      fludarabine IV over 30 minutes on days -5 to -1. Patients planning to receive family member&#xD;
      HLA-mismatched or unrelated bone marrow transplantation receive horse anti-thymocyte globulin&#xD;
      IV once daily on days -5 and -4. Patients undergo allogeneic T-cell-depleted bone marrow&#xD;
      transplantation on day 0. Patients receive filgrastim (G-CSF) IV every 12 hours beginning on&#xD;
      day 7 and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed every 2-4 weeks for the first 100 days post-transplantation, every 6&#xD;
      weeks for 6 months, every 3 months for 1 year, and then every 3-6 months until 2 years&#xD;
      post-transplantation.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients (25 with HLA 6/6 antigen-matched related donors and&#xD;
      25 with HLA 5/6 antigen-matched related donors or HLA 5/6 or 6/6 antigen-matched unrelated&#xD;
      donors) will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal transplantation related mortality</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>High disease-free survival at 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pts &lt; than or = 18 years with lymphohematopoietic disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase II, single-center study to evaluate a cytoreductive regimen of hyperfractionated TBI, thiotepa and cyclophosphamide (HFTBI/thio/cy) followed by infusions of SBA-E- T-cell depleted marrow in pediatric leukemia recipients of either HLA-identical or HLA-1Ag non-identical related or unrelated donors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>Pts &lt; than or = 18 years with lymphohematopoietic disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Pts &lt; than or = 18 years with lymphohematopoietic disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Pts &lt; than or = 18 years with lymphohematopoietic disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Pts &lt; than or = 18 years with lymphohematopoietic disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <arm_group_label>Pts &lt; than or = 18 years with lymphohematopoietic disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <arm_group_label>Pts &lt; than or = 18 years with lymphohematopoietic disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Pts &lt; than or = 18 years with lymphohematopoietic disorders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following diagnoses:&#xD;
&#xD;
               -  Histologically confirmed good-risk acute myeloid leukemia (AML) in first&#xD;
                  remission with an HLA-compatible related donor&#xD;
&#xD;
                    -  Ineligible for unrelated bone marrow transplantation unless failed&#xD;
                       first-line induction chemotherapy or have molecular evidence of disease at&#xD;
                       time of transplantation&#xD;
&#xD;
               -  Histologically confirmed high-risk AML in first remission&#xD;
&#xD;
                    -  High risk defined by cytogenetics, biphenotypic and undifferentiated&#xD;
                       leukemia phenotype, secondary AML, or AML after myelodysplastic syndromes&#xD;
                       (MDS)&#xD;
&#xD;
                    -  Eligible for related or unrelated donor transplantation&#xD;
&#xD;
               -  Histologically confirmed acute lymphoblastic leukemia (ALL) or lymphoblastic&#xD;
                  lymphoma (LL) in first remission with high risk for relapse or in second or third&#xD;
                  remission&#xD;
&#xD;
                    -  High risk for relapse defined by hypodiploidy, pseudodiploidy with&#xD;
                       translocations t(9;22) or infant t(4;11), or failure to achieve remission&#xD;
                       after four weeks of induction therapy&#xD;
&#xD;
                    -  Eligible for related or unrelated donor transplantation&#xD;
&#xD;
               -  Histologically confirmed chronic myelogenous leukemia (CML) in at least first&#xD;
                  chronic phase or acceleration with an HLA-compatible related donor&#xD;
&#xD;
               -  Histologically confirmed CML in first chronic phase if failed conventional&#xD;
                  therapy or in at least second chronic phase or acceleration with an&#xD;
                  HLA-compatible unrelated donor&#xD;
&#xD;
               -  Histologically confirmed non-Hodgkin's lymphoma beyond first complete remission&#xD;
                  or primary induction failure and tumors that are chemosensitive defined as at&#xD;
                  least 50% reduction in mass size&#xD;
&#xD;
                    -  Eligible for related or unrelated donor transplantation&#xD;
&#xD;
               -  Histologically confirmed MDS with intermediate or high-risk disease defined by&#xD;
                  International Prognostic Scoring System and paroxysmal nocturnal hematuria&#xD;
&#xD;
                    -  Eligible for related or unrelated donor transplantation&#xD;
&#xD;
          -  Treatment-related MDS or leukemia allowed if primary malignancy (e.g., neuroblastoma&#xD;
             or Ewing's sarcoma) at low risk of recurrence&#xD;
&#xD;
          -  No AML, ALL, or LL in relapse or greater than third remission&#xD;
&#xD;
          -  No CML in blast crisis defined as more than 30% blasts plus promyelocytes&#xD;
&#xD;
          -  No active CNS involvement&#xD;
&#xD;
          -  History of leukemia cutis allowed&#xD;
&#xD;
          -  HLA compatible donor available&#xD;
&#xD;
               -  5/6 or 6/6 HLA antigen matched related or unrelated&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100% OR&#xD;
&#xD;
          -  Lansky 50-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 3 times ULN (unless liver involvement is present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 50% at rest (if less than 50% at rest, must increase with exercise)&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Asymptomatic with no prior risk features OR&#xD;
&#xD;
          -  DLCO greater than 40% predicted (corrected for hemoglobin) if symptomatic&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV I/II negative&#xD;
&#xD;
          -  No uncontrolled viral, bacterial, or fungal infection&#xD;
&#xD;
          -  No known hypersensitivity to bovine proteins&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characterisitics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy that would preclude total body irradiation dose&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy A. Kernan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

